middle-income countries for access to orphan drugs. Andrea Messori and colleagues are convinced that price should be determined only on how much value patients receive from a drug; a similar argument is presented by Jaume Puig-Junoy and Carlos Campillo-Artero. We disagree for several reasons. First, the health technology assessment (HTA) community has developed methods for assessing efficacy and effectiveness, but they have always come up against the task of attributing a dollar value figure to 1 year of quality life, which has kept changing, from US$30 000 to $40 000 and now $60 000. Second, with respect to orphan drugs, HTA has been unable to enforce the quality-adjusted life-year approach. Finally, production costs have been left out of the HTA because they are regarded as difficult to assess. However, the notion that these could be dangerously inflated has never been tested for orphan drugs. For price negotiation, production costs would be a more robust criterion than the approach that is being used at the moment, 1 and both costs and values ought to be considered. Puig-Junoy and Campillo-Artero further maintain that a European price is not indispensable. Judging from the current pattern, whereby what has been agreed by one country is then used to persuade other countries to accept the same price, we find this procedure neither efficient nor enlightened. Since the price of any individual orphan medicinal product in different European countries varies by a maximum range of a 15% price increase or decrease, the advantage of a country-by-country negotiation is only theoretical. A uniform price negotiated on behalf of Europe as a single block by the European Medicines Agency would be almost certainly lower than it is now in any European country; we cannot think reported that a reform carried out by Mali will not be rolled out until 2020, but the reform is planned to begin in 2019 through a phased roll-out. The text now reads: "will not become fully effective until 2022 because of the numerous changes needed to ensure smooth roll-out", and the title of the paragraph now reads: "Not fully rolled out until 2020". These corrections have been made to the online version as of April 18, 2019.
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